COMP <GO>
BRKR vs ALMR // EV/EBITDA & P/E VALUATION
Bruker Corporation (NASDAQ) VS. Alamar Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: BRKR 3
— ALMR 0
■ METRIC PARITY
LAST: $62.00 (0.00%) • MKT CAP: $9.45B
valuation
75.7x
LAST: $34.04 (-0.76%) • MKT CAP: $2.36B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. ALMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | ALMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 75.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 2.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -0.20% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 0.00% | +0.24 | BRKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.2 | 50.8 | +5.39 | BRKR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.45B | $2.36B | $7.08B | BRKR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | ALMR REV | BRKR GROSS % | ALMR GROSS % | BRKR FCF | ALMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $0 | 45.9% | — | $43.3M | — |
| FY 2024 | $3.37B | — | 49.0% | — | $136.0M | — |
| FY 2023 | $2.96B | — | — | — | $216.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
ALMR // BETA —